Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + Trastuzumab + Dalpiciclib + Letrozole vs TCHP in HR+/HER2+ Breast Cancer
NCT05638594Phase 2Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pyrotinib and dalpiciclib in breast cancer (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Total Pathologic Complete Response Rate at 3 years. Started Dec 2022; status: recruiting.
02
Drugs
pyrotinibdalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05638594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638594.